Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by Rigshospitalet, Denmark.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00375635
First received: September 12, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted

September 12, 2006
September 12, 2006
March 2006
Not Provided
  • Blood pressure
  • Safety serological parameters
  • Concentrations of protein bound uremic toxins
Same as current
No Changes Posted
Bleeding episodes
Same as current
Not Provided
Not Provided
 
Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis
Removal of Protein Bound Uremic Toxins in Chronic Hemodialysis Patients by Modified Plasma Separation and Adsorption Combined With Hemodialysis

The aim of this study is to examine removal of protein bound uremic substances by mFPSA in chronic hemodialysis patients. mFPSA is an extracorporal blood purification system developed for detoxification in acute liver failure by removal of protein bound as well as water soluble substances.

Measurements of uremic protein bound substances before and after mFPSA and a preceding routine hemodialysis session.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Uremia
Procedure: mFPSA treatment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
October 2006
Not Provided

Inclusion Criteria:

  • Over the age of 18
  • Anuria
  • Chronic hemodialysis dependence

Exclusion Criteria:

  • No present history of bleeding episodes
  • Cardiac diseases
Both
18 Years to 70 Years
No
Contact: Mette B Damholt, MD,Ph.d. +45 35453545 ext 50589 damholt@dadlnet.dk
Contact: Soren D Ladefoged, MD +45 35453545 ext 51020 SOERENRH04736LADEFOGED@rh.dk
Denmark
 
NCT00375635
MBD2006
Not Provided
Not Provided
Rigshospitalet, Denmark
Not Provided
Principal Investigator: Mette B Damholt, MD,Ph.d. Rigshospitalet P2132
Principal Investigator: Soren D Ladefoged, MD Rigshospitalet, Denmark
Rigshospitalet, Denmark
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP